MedTrace Logo

Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study

NCT06946849 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-04-27

No results posted yet for this study

Summary

Second-line regimen with or without consolidative radiotherapy in patients with oligometastatic/locally advanced unresectable intrahepatic cholangiocarcinoma: an open-label, randomised, controlled study.

Conditions

  • Intrahepatic Cholangiocarcinoma (Icc)

Interventions

RADIATION

radiotherapy

Radiotherapy

DRUG

FOLFIRI or FOLFOX or Regorafenib

FOLFIRI or FOLFOX or Regorafenib

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Zhaochong Zeng · Zhongshan Hospital, Fudan Unuversity

  • Guoming Shi · Zhongshan Hospital, Fudan Unuversity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06946849 on ClinicalTrials.gov